The Biologics Prescribers Collaborative (BPC), an organization comprising 6 member groups whose memberships prescribe biologic agents, has released its comment letter to the FDA on the agency’s Considerations in Demonstrating Interchangeability With a Reference Product draft guidance, calling on the FDA to do more to “promote transparency and patient safety."
The Biologics Prescribers Collaborative (BPC), an organization comprising 6 member groups whose memberships prescribe biologic agents, has released its comment letter to the FDA on the agency’s Considerations in Demonstrating Interchangeability With a Reference Product draft guidance.
In its letter, BPC commended the FDA for its care in developing the draft guidance, yet called upon the agency to “promote transparency and patient safety by paying particular attention to the data, including robust clinical switching studies, required to demonstrate interchangeability” as a means by which to build prescribers’ confidence in treating patients with interchangeable biosimilars.
BPC’s comment letter included 5 key requests:
Such calls for further studies and a greater burden of evidence are consistent with research showing that US clinicians lack familiarity with and confidence in prescribing biosimilar products, and that they require further data before they will be receptive to the idea of switching to biosimilars from reference products.
While it is unsurprising that provider groups such as BPC would call for greater evidence of the safety and efficacy of biosimilar products, some industry voices point out that more robust studies may cause patients to shoulder an extra burden. Anna Rose Welch of Biosimilar Development noted the increased workload that the BPC’s recommendations would require of patients. “This work won’t just be on companies’ shoulders,” Welch writes. “A lot of this pressure will also be placed on the patient…studies involve lots of blood samplings and can boast higher dropout rates, which suggest this high burden on patients.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.